secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001628280-22-029456
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M
--------------------------------------------------------------------------

- Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.
- Up to $160M in milestones: $50M on Phase 3 enrollment, $50M on FDA approval, $60M after annual royalty receipt threshold.
- Arrowhead retains eligibility for all milestone payments from Amgen under the original license agreement.
- Transaction provides non-dilutive cash to fund Arrowhead's pipeline and operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/0001628280-22-029456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/arwr-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer